| Identification | Back Directory | [Name]
ABT-418 HYDROCHLORIDE | [CAS]
147388-83-8 | [Synonyms]
ABT-418 HCl
ABT-418 HYDROCHLORIDE
(S)-3-Methyl-5-(1-methylpyrrolidin-2-yl)-isoxazolea€￠HCl
3-Methyl-5-[(2S)-1-Methylpyrrolidin-2-yl]isoxazole hydrochloride | [Molecular Formula]
C9H14N2O.ClH | [MDL Number]
MFCD00870490 | [MOL File]
147388-83-8.mol | [Molecular Weight]
202.684 |
| Chemical Properties | Back Directory | [storage temp. ]
-20°C | [solubility ]
H2O: 15 mg/mL, soluble
| [form ]
solid
| [color ]
white to off-white
| [Water Solubility ]
H2O: soluble 15mg/mL | [Stability:]
Stable for 1 year from date of purchase as supplied. Solutions in distilled water may be stored at -20°C for up to 3 months. |
| Hazard Information | Back Directory | [Description]
ABT-418 (CAS 147388-83-8) is an agonist at neuronal nicotinic acetylcholine receptors displaying the highest potency at α4β2 and α2β2 subtypes (EC50= approximately 6 and 11 μM, respectively).1 Displays anxiolytic activity in a rat model and was 6-fold more potent than diazepam.2 Reduces distractibility in a primate model3 and may have relevance in attention deficit hyperactivity disorder4. Improves cognition in Alzheimer’s disease patients.5 | [Uses]
ABT-418 Hydrochloride is a neuronal nicotinic acetylcholine receptor agonist or activator which can be synthesized from L-proline. | [in vivo]
ABT-418 hydrochloride (125.66 μg/kg; i.p.) induces a significant increase in the time spent by the rats in the open arms of the elevated plus maze[1].
Acute administration of ABT-418 (125.66μg/kg; i.p.) also attenuates the anxiogenic-like effect elicited by withdrawal from chronic (-)-nicotine treatment[1].
ABT-418 hydrochloride (0.6 mg/kg; i.p.; daily; for two weeks) effectively improves spatial memory in an animal model of ADHD[2].
ABT-418 hydrochloride significantly enhances the cortical α4 and β2 nAChR subunits and the hippocampal α4 subunit expression[2].
| Animal Model: | Male SHRs (4–5 weeks old), attention deficit hyperactivity disorder (ADHD) model[2] | | Dosage: | 0.6 mg/kg | | Administration: | Intraperitoneal injection; once daily; for two weeks | | Result: | Effectively improved spatial memory. |
| [storage]
4°C, away from moisture | [References]
1) Papke et al. (1997), Activation and inhibition of rat neuronal nicotinic receptors by ABT-418; Br. J. Pharmacol., 120 429
2) Brioni et al. (1994), Anxiolytic-like effects of the novel cholinergic channel activator ABT-418; J. Pharmacol. Exp. Therap., 271 353
3) Prendergast et al. (1998), Central nicotinic receptor agonists ABT-418, ABT089, and (-)-nicotine reduce distractibility in adult monkey; Psychopharmacology (Berl), 136 50
4) Beiderman and Spencer (2000), Non-stimulant treatments for ADHD; Eur. Child Adolesc. Psychiatry, 9 Suppl1 151
5) Potter et al. (1999), Acute effects of the selective cholinergic channel activator (nicotinic agonist) ABT-418 in Alzheimer’s disease; Psychopharmacology (Berl), 142 334 |
|
| Company Name: |
BOC Sciences
|
| Tel: |
1-631-485-4226; 16314854226 |
| Website: |
https://www.bocsci.com |
| Company Name: |
Energy Chemical
|
| Tel: |
021-58432009 400-005-6266 |
| Website: |
http://www.energy-chemical.com |
| Company Name: |
Merck KGaA
|
| Tel: |
(+86) 21 2033 8288 |
| Website: |
http://www.sigmaaldrich.cn |
|